Prometrium Drug-Drug Interactions: Complete Clinical Profile for Micronized Progesterone

How Prometrium Works: Mechanism and Metabolic Pathway

Micronized progesterone binds the intracellular progesterone receptor (PR-A and PR-B isoforms), triggering nuclear translocation and transcriptional regulation of target genes in the endometrium, breast, and central nervous system [1]. This is identical to endogenous progesterone. The oral micronization process reduces particle size to 5-10 micrometers, which improves gastrointestinal absorption compared with non-micronized crystalline progesterone [2].

After oral ingestion, micronized progesterone undergoes extensive first-pass hepatic metabolism. CYP3A4 serves as the dominant enzyme, converting progesterone into 5-alpha and 5-beta reduced metabolites, including allopregnanolone (a potent GABA-A receptor modulator responsible for the drug's sedative properties) and pregnanediol [3]. CYP2C19 contributes a secondary metabolic route. This dual-enzyme clearance creates the pharmacokinetic foundation for every drug interaction discussed below.

Peak serum concentrations occur within 2-4 hours of oral dosing. Food co-administration increases the area under the curve (AUC) by approximately 25-50% according to the FDA-approved labeling, which is why the prescribing information recommends administration at bedtime, ideally without a high-fat meal if consistent dosing is the clinical goal [4]. Protein binding ranges from 96% to 99%, primarily to albumin and corticosteroid-binding globulin (CBG), meaning displacement interactions are theoretically possible but rarely clinically significant at standard HRT doses of 100-200 mg daily.

CYP3A4 Inhibitors: The Highest-Impact Interaction Category

Strong CYP3A4 inhibitors produce the most clinically meaningful changes in micronized progesterone pharmacokinetics. Ketoconazole, a prototypical strong inhibitor, increases progesterone AUC by roughly 300% based on in vitro microsomal data and clinical pharmacokinetic modeling [5]. This magnitude of change can intensify both the desired endometrial effect and the unwanted sedation, dizziness, and breast tenderness that patients report.

The practical drug list includes ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, cobicistat-containing HIV regimens, and nefazodone. Grapefruit juice also inhibits intestinal CYP3A4, though the effect is less predictable and generally smaller in magnitude (estimated 20-40% AUC increase depending on volume consumed) [6].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School, has noted: "Clinicians prescribing progesterone in the context of combination HRT need to evaluate the entire medication list for CYP3A4 interference, because both under-dosing and over-dosing carry endometrial consequences" [7].

When a strong CYP3A4 inhibitor cannot be avoided, reducing the Prometrium dose from 200 mg to 100 mg nightly is a reasonable first step. Serum progesterone levels drawn 4-6 hours post-dose can confirm whether endometrial exposure remains adequate. The clinical target for endometrial protection is a mid-luteal equivalent serum progesterone concentration above 5 ng/mL, though individual variation exists [8].

Moderate CYP3A4 inhibitors (erythromycin, diltiazem, verapamil, fluconazole, aprepitant) increase progesterone exposure to a lesser degree, typically 50-150%. These warrant vigilance rather than automatic dose adjustment. Monitor the patient for excessive sedation and breakthrough bleeding patterns during the first 2-3 cycles after the interacting drug is added.

CYP3A4 Inducers: Risk of Therapeutic Failure

CYP3A4 inducers accelerate progesterone clearance and can drop serum levels below the threshold needed for reliable endometrial protection. This is not a minor concern. Unopposed estrogen exposure from inadequate progesterone dosing raises the relative risk of endometrial hyperplasia by 5- to 10-fold over 3-5 years of use [9].

Rifampin is the most potent offender. As the strongest known CYP3A4 inducer, rifampin can reduce the AUC of CYP3A4 substrates by 80-90%. Applied to a 200 mg Prometrium dose, this could leave effective circulating progesterone at levels equivalent to 20-40 mg, well below what the PEPI trial (N=875) validated as protective [10].

Other clinically relevant inducers include:

• Anticonvulsants: phenytoin, carbamazepine, phenobarbital, oxcarbazepine, topiramate (moderate)
• Anti-infectives: rifabutin, efavirenz, nevirapine
• Herbal: St. John's Wort (Hypericum perforatum)
• Other: bosentan, modafinil (weak-to-moderate)

For patients on enzyme-inducing anticonvulsants, the 2022 Endocrine Society Clinical Practice Guideline on menopausal hormone therapy recommends considering non-oral progesterone delivery (vaginal micronized progesterone gel or the levonorgestrel IUD) to bypass first-pass hepatic metabolism entirely [11]. If oral Prometrium must be used, dose escalation to 300 mg nightly with endometrial surveillance via transvaginal ultrasound every 6-12 months is a documented strategy, though supporting trial data are limited.

St. John's Wort deserves specific mention because patients often do not volunteer herbal supplement use. A 2004 pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that St. John's Wort reduced oral contraceptive progestin levels enough to cause breakthrough bleeding in 30% of participants [12]. The same mechanism applies to micronized progesterone.

CYP2C19 Interactions: A Secondary but Real Pathway

CYP2C19 contributes approximately 15-25% of total micronized progesterone clearance based on in vitro reaction phenotyping studies [3]. Drugs that inhibit CYP2C19, such as omeprazole, esomeprazole, fluoxetine, fluvoxamine, and ticlopidine, may modestly increase progesterone exposure by 20-40% when CYP3A4 is not simultaneously induced.

This becomes clinically interesting in two scenarios. First, when a patient takes both a CYP3A4 inhibitor and a CYP2C19 inhibitor (for example, fluconazole plus omeprazole), the combined effect can approximate that of a strong CYP3A4 inhibitor alone. Second, CYP2C19 poor metabolizers, who represent approximately 2-5% of Caucasians and 15-25% of East Asians, may experience higher baseline progesterone levels on standard doses [13]. These patients sometimes report pronounced sedation at 200 mg that resolves at 100 mg.

Fluvoxamine is worth flagging specifically. It is both a strong CYP2C19 inhibitor and a moderate CYP3A4 inhibitor. Co-administration with Prometrium 200 mg has been associated with excessive daytime somnolence in case reports, and dose reduction to 100 mg typically resolves the issue [14].

CNS Depressants: Additive Sedation Through GABA-A Modulation

The sedative effect of oral micronized progesterone is not a side effect in the traditional sense. It is a direct pharmacological consequence of allopregnanolone, a 5-alpha reduced metabolite that acts as a positive allosteric modulator at the GABA-A receptor, the same molecular target as benzodiazepines, barbiturates, and alcohol [15]. This mechanism explains why the FDA label directs patients to take Prometrium at bedtime.

Co-administration with other GABA-active or CNS-depressant drugs creates predictable additive sedation. The relevant drug categories include:

• Benzodiazepines: alprazolam, lorazepam, diazepam, clonazepam
• Non-benzodiazepine hypnotics: zolpidem, eszopiclone, zaleplon
• Opioid analgesics: hydrocodone, oxycodone, tramadol, morphine
• Gabapentinoids: gabapentin, pregabalin
• Sedating antihistamines: diphenhydramine, hydroxyzine, doxepin (low-dose)
• Alcohol

A 2018 pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data identified progesterone-benzodiazepine co-prescriptions as carrying a 2.3-fold higher reporting odds ratio for excessive sedation events compared with either drug alone [16]. While FAERS data cannot establish causation, the disproportionality signal aligns with the known pharmacology.

The clinical management approach is straightforward. If a patient requires both Prometrium and a benzodiazepine or Z-drug, separate the dosing by at least 2 hours and counsel on fall risk. For patients older than 65, the American Geriatrics Society Beers Criteria already flag both benzodiazepines and exogenous progesterone individually; the combination adds another reason to seek alternatives [17].

Anticoagulants and Antiplatelet Agents

Progesterone has mild procoagulant properties at supraphysiologic concentrations, though the effect is substantially weaker than that of synthetic progestins like medroxyprogesterone acetate (MPA). The PEPI trial demonstrated that micronized progesterone preserved favorable changes in HDL cholesterol and did not significantly alter coagulation markers (fibrinogen, factor VII) at 200 mg/day when combined with conjugated equine estrogens [10].

For patients on warfarin, the interaction is pharmacodynamic rather than pharmacokinetic. Progesterone does not significantly inhibit or induce CYP2C9 (the primary warfarin-metabolizing enzyme). There are isolated case reports of INR fluctuation after starting or stopping HRT containing micronized progesterone, but these typically reflect the estrogen component's effect on clotting factor synthesis rather than a direct progesterone-warfarin interaction [18].

The 2017 American College of Chest Physicians guideline recommends checking INR within 5-7 days of initiating or discontinuing any hormone therapy in patients on stable warfarin [19]. Direct oral anticoagulants (DOACs) such as apixaban and rivarelbaban are CYP3A4 substrates, creating theoretical concern for competitive inhibition at the enzyme level. In practice, at Prometrium's standard 100-200 mg dose, this interaction has not produced clinically meaningful changes in DOAC levels.

Antidiabetic Medications and Metabolic Effects

Progesterone has a mild insulin-antagonistic effect. In the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, fasting glucose increased by a mean of 1.2 mg/dL in the micronized progesterone arm compared with placebo, a statistically detectable but clinically marginal change [10]. This contrasts with MPA, which produced a 3.1 mg/dL mean increase in the same trial.

For patients on metformin, sulfonylureas, or insulin, the interaction is minimal at standard HRT doses. No dose adjustments to antidiabetic medications are routinely required when starting Prometrium 100-200 mg. Patients on tight glycemic control (HbA1c target <7.0%) may benefit from more frequent glucose monitoring during the first 4-6 weeks.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) slow gastric emptying, which could theoretically delay the absorption of oral micronized progesterone. No published pharmacokinetic studies have specifically evaluated this combination. Because Prometrium is taken at bedtime and GLP-1 agonists are typically injected in the morning, the temporal separation likely minimizes any absorption effect in practice.

Thyroid Hormones and Corticosteroids

Oral estrogen (the usual co-prescribed HRT component) increases thyroxine-binding globulin (TBG), which can raise levothyroxine dose requirements by 20-30% [20]. Micronized progesterone itself does not significantly alter TBG levels. Patients who attribute rising TSH to their "HRT" after starting combined estrogen-progesterone therapy should understand that the estrogen, not the Prometrium, is the responsible agent.

The 2014 American Thyroid Association guideline recommends re-checking TSH 6-8 weeks after initiating oral estrogen therapy and adjusting levothyroxine accordingly [21]. Transdermal estradiol avoids this interaction because it bypasses hepatic TBG synthesis, and micronized progesterone can be paired with either route.

Exogenous corticosteroids (prednisone, dexamethasone) compete with progesterone for binding to corticosteroid-binding globulin (CBG). At high corticosteroid doses (prednisone >20 mg/day), this displacement could transiently increase free progesterone concentrations, though the clinical significance is uncertain given progesterone's own rapid clearance.

Dr. Nanette Santoro, professor of obstetrics and gynecology at the University of Colorado School of Medicine, has stated: "The beauty of micronized progesterone over synthetic progestins is its cleaner interaction profile, but 'cleaner' does not mean 'absent.' Any woman on polypharmacy deserves a CYP3A4 audit when we add Prometrium" [22].

Hormonal Contraceptives and Other Progestogens

Combining Prometrium with another progestogenic agent (norethindrone, drospirenone, levonorgestrel IUD, medroxyprogesterone acetate) is uncommon but occasionally seen during transition periods or in complex endocrine regimens. The interaction is purely pharmacodynamic: additive progestogenic effects including increased sedation, breast tenderness, bloating, and mood changes.

There is no pharmacokinetic competition at CYP3A4 that would alter clearance rates of either progestogen significantly, because synthetic progestins and micronized progesterone are metabolized to different end products. The concern is excessive progestogenic stimulation of the endometrium, which paradoxically can cause irregular bleeding through progesterone-withdrawal breakthrough patterns.

Concomitant use of micronized progesterone with combined oral contraceptives is not standard practice and lacks safety data. If a perimenopausal patient is transitioning from a combined OC to HRT, a washout period of one menstrual cycle is typical before starting the estrogen-plus-Prometrium regimen.

Food and Supplement Interactions

Oral micronized progesterone's absorption is significantly affected by food. The FDA labeling reports that a high-fat meal increases Cmax by 2- to 5-fold and AUC by 25-50% compared with fasting administration [4]. This is one of the larger food effects among commonly prescribed HRT agents. Consistent timing relative to meals matters more than absolute avoidance of food; patients should choose one approach (fed or fasted) and maintain it.

Grapefruit juice inhibits intestinal CYP3A4 and can increase progesterone exposure modestly (estimated 20-40%). A single 8-ounce glass is unlikely to cause problems, but habitual large-volume consumption (more than 1 liter daily) could push exposure into ranges associated with excessive sedation.

Black cohosh, dong quai, and red clover contain phytoestrogens that do not directly interact with micronized progesterone pharmacokinetics, but they may alter the clinical estrogen-progesterone balance in unpredictable ways. The North American Menopause Society (NAMS) 2022 position statement recommends documenting all herbal supplement use in patients on HRT and re-evaluating any time breakthrough bleeding or mood changes emerge [23].